TY - JOUR
T1 - Transmission-Blocking Vaccines for Canine Visceral Leishmaniasis
T2 - New Progress and Yet New Challenges
AU - Leite, Jaqueline Costa
AU - Gonçalves, Ana Alice Maia
AU - de Oliveira, Diana Souza
AU - Resende, Lucilene Aparecida
AU - Boas, Diego Fernandes Vilas
AU - Ribeiro, Helen Silva
AU - Pereira, Diogo Fonseca Soares
AU - da Silva, Augusto Ventura
AU - Mariano, Reysla Maria da Silveira
AU - Reis, Pedro Campos Carvalhaes
AU - Nakasone, Eiji Nakasone
AU - França-Silva, João Carlos
AU - Galdino, Alexsandro Sobreira
AU - Paes, Paulo Ricardo de Oliveira
AU - Melo, Marília Martins
AU - Dias, Edelberto Santos
AU - Chávez-Fumagalli, Miguel Angel
AU - da Silveira-Lemos, Denise
AU - Dutra, Walderez Ornelas
AU - Giunchetti, Rodolfo Cordeiro
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/10
Y1 - 2023/10
N2 - Dogs with visceral leishmaniasis play a key role in the transmission cycle of Leishmania infantum to humans in the urban environment. There is a consensus regarding the importance of developing a vaccine to control this disease. Despite many efforts to develop a protective vaccine against CVL, the ones currently available, Leish-tec® and LetiFend®, have limited effectiveness. This is due, in part, to the complexity of the immune response of the naturally infected dogs against the parasite and the complexity of the parasite transmission cycle. Thus, strategies, such as the development of a transmission-blocking vaccines (TBVs) already being applied to other vector-borne diseases like malaria and dengue, would be an attractive alternative to control leishmaniasis. TBVs induce the production of antibodies in the vertebrate host, which can inhibit parasite development in the vector and/or interfere with aspects of vector biology, leading to an interruption of parasite transmission. To date, there are few TBV studies for CVL and other leishmaniasis forms. However, the few studies that exist show promising results, thus justifying the further development of this approach.
AB - Dogs with visceral leishmaniasis play a key role in the transmission cycle of Leishmania infantum to humans in the urban environment. There is a consensus regarding the importance of developing a vaccine to control this disease. Despite many efforts to develop a protective vaccine against CVL, the ones currently available, Leish-tec® and LetiFend®, have limited effectiveness. This is due, in part, to the complexity of the immune response of the naturally infected dogs against the parasite and the complexity of the parasite transmission cycle. Thus, strategies, such as the development of a transmission-blocking vaccines (TBVs) already being applied to other vector-borne diseases like malaria and dengue, would be an attractive alternative to control leishmaniasis. TBVs induce the production of antibodies in the vertebrate host, which can inhibit parasite development in the vector and/or interfere with aspects of vector biology, leading to an interruption of parasite transmission. To date, there are few TBV studies for CVL and other leishmaniasis forms. However, the few studies that exist show promising results, thus justifying the further development of this approach.
KW - canine visceral leishmaniasis
KW - transmission-blocking vaccines
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85175335877&partnerID=8YFLogxK
U2 - 10.3390/vaccines11101565
DO - 10.3390/vaccines11101565
M3 - Review article
AN - SCOPUS:85175335877
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 10
M1 - 1565
ER -